Payment overview · 2025
General Payments
$598.51
39 reported records · 11 companies
Healthcare provider profile · identity verified
Michael David Mcdaniel, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · THOMSON, GA · NPI 1932327996
Verified facts
What the public records show
CMS Open Payments records show Michael David Mcdaniel, P.A. received $598.51 in general payments during 2025 across 39 reported records.
ABBVIE INC. accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $159.92 | 26.7% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.50 | 12.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $68.94 | 11.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $63.73 | 10.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.93 | 9.8% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $57.68 | 9.6% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $38.44 | 6.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.44 | 4.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.40 | 3.1% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $17.77 | 3.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.76 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $598.51 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.50 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $68.94 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $63.73 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.93 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $57.68 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $54.78 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.31 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.09 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.72 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.87 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $38.44 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $36.71 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.69 | 4 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 243 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
267 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
243 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 857 | 241 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 704 | 201 |
| Atorvastatin Calcium | Atorvastatin Calcium | 625 | 176 |
| Metformin Hcl | Metformin Hcl | 619 | 167 |
| Lisinopril | Lisinopril | 580 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 562 | 139 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 488 | 123 |
| Tramadol Hcl | Tramadol Hcl | 454 | 104 |
| Losartan Potassium | Losartan Potassium | 445 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 441 | 126 |
| Gabapentin | Gabapentin | 420 | 116 |
| Fluticasone Propionate | Fluticasone Propionate | 399 | 143 |
| Famotidine | Famotidine | 328 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 87 |
| Simvastatin | Simvastatin | 290 | 79 |
| Omeprazole | Omeprazole | 274 | 68 |
| Jardiance | Empagliflozin | 267 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 74 |
| Meloxicam | Meloxicam | 259 | 71 |
| Potassium Chloride | Potassium Chloride | 256 | 70 |
| Furosemide | Furosemide | 249 | 72 |
| Ozempic | Semaglutide | 243 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 66 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 214 | 57 |
| Methocarbamol | Methocarbamol | 206 | 68 |
| Allopurinol | Allopurinol | 202 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 198 | 49 |
| Trazodone Hcl | Trazodone Hcl | 193 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 52 |
| Sertraline Hcl | Sertraline Hcl | 192 | 54 |
| Eliquis | Apixaban | 191 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 188 | 55 |
| Prednisone | Prednisone | 182 | 114 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 177 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 173 | 42 |
| Pregabalin | Pregabalin | 169 | 35 |
| Carvedilol | Carvedilol | 146 | 43 |
| Alprazolam | Alprazolam | 139 | 21 |
| Clonazepam | Clonazepam | 133 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 130 | 65 |
| Lovastatin | Lovastatin | 125 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 121 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 120 | 34 |
| Meclizine Hcl | Meclizine Hcl | 119 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 114 | 30 |
| Atenolol | Atenolol | 113 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 31 |
| Spironolactone | Spironolactone | 104 | 34 |
| Alendronate Sodium | Alendronate Sodium | 102 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 20 |
| Bupropion Xl | Bupropion Hcl | 99 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 97 | 26 |
| Ibuprofen | Ibuprofen | 97 | 26 |
| Promethazine Hcl | Promethazine Hcl | 97 | 16 |
| Valsartan | Valsartan | 92 | 23 |
| Farxiga | Dapagliflozin Propanediol | 89 | 21 |
| Fluconazole | Fluconazole | 88 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 19 |
| Buspirone Hcl | Buspirone Hcl | 87 | 16 |
| Donepezil Hcl | Donepezil Hcl | 85 | 25 |
| Montelukast Sodium | Montelukast Sodium | 81 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 78 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 23 |
| Warfarin Sodium | Warfarin Sodium | 76 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 19 |
| Glimepiride | Glimepiride | 74 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 58 |
| Symbicort | Budesonide/Formoterol Fumarate | 69 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 19 |
| Januvia | Sitagliptin Phosphate | 66 | 16 |
| Methylprednisolone | Methylprednisolone | 64 | 50 |
| Azithromycin | Azithromycin | 63 | 52 |
| Linzess | Linaclotide | 63 | 15 |
| Estradiol | Estradiol | 60 | 15 |
| Mirtazapine | Mirtazapine | 60 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 14 |
| Ondansetron Odt | Ondansetron | 58 | 26 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 56 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 16 |
| Fenofibrate | Fenofibrate | 53 | 12 |
| Valacyclovir | Valacyclovir Hcl | 53 | 17 |
| Lorazepam | Lorazepam | 52 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 11 |
| Amoxicillin | Amoxicillin | 49 | 41 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 13 |
| Cephalexin | Cephalexin | 43 | 31 |
| Glipizide | Glipizide | 43 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 11 |
| Metformin Hcl Er | Metformin Hcl | 42 | 16 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Glipizide Er | Glipizide | 39 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Finasteride | Finasteride | 38 | 14 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Vraylar | Cariprazine Hcl | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 25 |
| Sucralfate | Sucralfate | 36 | 18 |
| Colchicine | Colchicine | 35 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 27 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 32 | suppressed |
| Glyburide | Glyburide | 32 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 12 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Roflumilast | Roflumilast | 24 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 23 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Prolia | Denosumab | 22 | 16 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Terconazole | Terconazole | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Imiquimod | Imiquimod | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $598.51 · 39 records | ABBVIE INC. | ARISTADA, Auvelity, Briviact, CAPLYTA, CREON, Kerendia, LINZESS, LYBALVI, MINIMED 780G, MOUNJARO, NEFFY, Ozempic, QULIPTA, Rybelsus, Tymlos, UBRELVY, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error